AN EXTERNAL COMPOSITION FOR SKIN

Abstract

An object of the present invention is to provide an external composition for skin excellent in ultraviolet-ray absorbability. The present invention relates to the external composition for skin comprising (a) an ultraviolet-ray absorber, and (b) an inorganic phosphor. (a) The ultraviolet-ray absorber preferably contains at least one ultraviolet-ray absorber which absorbs UVB. Also, (a) the ultraviolet-ray absorber is more preferably at least one ultraviolet-ray absorber selected from the group consisting of 2-ethylhexyl paramethoxycinnamate, phenylbenzimidazole sulfonic acid, etc.

Claims

1. An external composition for skin which comprises (a) an ultraviolet-ray absorber and (b) an inorganic phosphor.

2. The external composition for skin according to claim 1, wherein (a) the ultraviolet-ray absorber contains at least one kind of an ultraviolet-ray absorber which absorbs UVB.

3. The external composition for skin according to claim 1, wherein (a) the ultraviolet-ray absorber is at least one kind of an ultraviolet-ray absorber selected from the group consisting of 2-ethylhexyl paramethoxycinnamate, phenylbenzimidazole sulfonic acid, isopropyl methoxycinnamate, octyl methoxycinnamate, para-amino-benzoic acid, ethyl PABA, ethyl-dihydroxypropyl PABA, ethylhexyl-dimethyl PABA, homosalate, ethylhexyl salicylate, 3-benzylidene camphor, 4-methylbenzylidene camphor, benzylidene camphor sulfonic acid, camphor benzalkonium methosulfate, polyacrylamidomethyl benzylidene camphor, diethylhexyl butamidotriazone, octyl triazone, disodium phenyl dibenzimidazole tetrasulfonate, a polyorganosiloxane having a benzalmalonate functional group, 4-tert-butyl-4-methoxybenzoylmethane, hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, 2-(2′-hydroxy-5 ‘ -methyl-phenyl)benzotriazole, 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl] -5-[(octyl)oxy]-phenol, 2-ethylhexyl dimethoxybenzylideneoxoimidazolidine propionate, 6-(4-methoxyphenyl)-1,3,5-triazine, tetrahydroxybenzophenone, 2-hydroxy-4-methoxy-benzophenone, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy} -phenyl]-drometrizole trisiloxane, 2,2’-methylenebis [6-(2H-benzotriazole-2-yl)-4-(1,1,3,3-tetramethyl-butyl)phenol] and octocrylene.

4. The external composition for skin according to claim 1, wherein (b) the inorganic phosphor is aluminate phosphor and/or titanate phosphor.

5. The external composition for skin according to claim 4, wherein the inorganic phosphor is an alkaline earth metal aluminate phosphor and/or an alkaline earth metal titanate phosphor.

6. The external composition for skin according to claim 5, wherein the alkaline earth metal aluminate phosphor is calcium manganese aluminate.

7. The external composition for skin according to claim 6, wherein the calcium manganese aluminate is represented by the following formula (1);
Ca.sub.XAl.sub.yO.sub.(2X+3Y+4Z)/2:Mn.sup.4+.sub.Z   (1) wherein 0.1<X<1.05, 11.9<Y≦12 and 0.0005<Z<0.1.

8. The external composition for skin according any one of claims 1 to 3, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate.

9. The external composition for skin according to any one of claims 1 to 3, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate and hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

10. The external composition for skin according to any one of claims 1 to 3, wherein a content of (b) the inorganic phosphor is 0.1 to 10% by mass based on the whole external composition for skin.

11. The external composition for skin according to any one of claims 1 to 3, wherein it is a sunscreen composition.

12. The external composition for skin according to claim 4, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate.

13. The external composition for skin according to claim 4, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate and hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

14. The external composition for skin according to claim 4, wherein a content of (b) the inorganic phosphor is 0.1 to 10% by mass based on the whole external composition for skin.

15. The external composition for skin according to claim 4, wherein it is a sunscreen composition.

16. The external composition for skin according to claim 5, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate.

17. The external composition for skin according to claim 5, wherein (a) the ultraviolet-ray absorber contains 2-ethylhexyl paramethoxycinnamate and hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

18. The external composition for skin according to claim 5, wherein a content of (b) the inorganic phosphor is 0.1 to 10% by mass based on the whole external composition for skin.

19. The external composition for skin according to claim 5, wherein it is a sunscreen composition.

Description

BRIEF EXPLANATION OF THE DRAWINGS

[0023] FIG. 1 is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0024] FIG. 2 is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0025] FIG. 3 is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0026] FIG. 4 is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0027] FIG. 5(a) is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0028] FIG. 5(b) is a drawing showing ultraviolet-ray absorbability of the external composition for skin which is an embodiment of the present invention.

[0029] FIG. 6 is a drawing showing a gene expression promotion effect of a vasodilator by red light irradiation.

EMBODIMENTS TO CARRY OUT THE INVENTION

[0030] In the following, the present invention is explained in detail.

[External Composition for Skin]

[0031] The external composition for skin of the present invention comprises (a) an ultraviolet-ray absorber, and (b) an inorganic phosphor. In addition, the external composition for skin of the present invention may contain other component(s) within the range which does not impair the effect of the present invention other than the essential components. In the following, these respective components are explained.

<(a) Ultraviolet-Ray Absorber>

[0032] (a) The ultraviolet-ray absorber is a compound which gives an ultraviolet-ray absorption effect to the external composition for skin of the present invention.

[0033] As (a) the ultraviolet-ray absorber, there may be mentioned 2-ethylhexyl paramethoxycinnamate, phenylbenzimidazole sulfonic acid, isopropyl methoxycinnamate, octyl methoxycinnamate, para-aminobenzoic acid, ethyl PABA, ethyl-dihydroxypropyl PABA, ethylhexyl-dimethyl PABA, homosalate, ethylhexyl salicylate, 3-benzylidene camphor, 4-methylbenzylidene camphor, benzylidene camphor sulfonic acid, camphor benzalkonium methosulfate, polyacrylamidomethyl benzylidene camphor, diethylhexyl butamidotriazone, octyl triazone, disodium phenyl dibenzimidazole tetrasulfonate, a polyorganosiloxane having a benzalmalonate functional group, etc., which are B wave (UV-B) absorbers; 4-tert-butyl-4-methoy-benzoylmethane, hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, 2-(2′-hydroxy-5′-methylphenyl)benzotriazole, 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-y1]-5-[(octyl)oxy]-phenol, 2-ethylhexyl dimethoxybenzylideneoxoimidazolidine propionate, etc., which are A wave (UV-A) absorbers; and 6-(4-methoxyphenyl)-1,3,5-triazine, tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]drometrizole trisiloxane, 2,2′-methylenebis[6-(2H-benzotriazole-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol], octocrylene, etc., which are AB wave absorbers, and the like. As (a) the ultraviolet-ray absorber, the above-mentioned ultraviolet-ray absorbers may be contained a single kind alone or may be contained two or more kinds.

[0034] Among these, as the ultraviolet-ray absorber contained in the external composition for skin of the present invention, from the viewpoint that a strengthening effect of ultraviolet-ray absorbability by (b) the inorganic phosphor can be easily obtained, it is preferred that at least one kind of a B wave (UV-B) absorbent (the ultraviolet-ray absorber which absorbs UVB) is contained, and more preferably 2-ethylhexyl paramethoxycinnamate is contained. It is also preferred that 2-ethylhexyl paramethoxycinnamate, and hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate or 6-(4-methoxyphenyl)-1,3,5-triazine are formulated in combination.

[0035] When the ultraviolet-ray absorbing component is formulated, an amount thereof to be used may be optionally selected in consideration with a feeling of use to a skin or an effect thereof, and it is, for example, 0.01 to 20% by mass, preferably 0.1 to 15% by mass based on the whole external composition for skin of the present invention.

<(b) Inorganic Phosphor>

[0036] In the external composition for skin of the present invention, an ultraviolet-ray absorption effect by (a) the ultraviolet-ray absorber can be markedly enhanced by containing (b) the inorganic phosphor.

[0037] (b) The inorganic phosphor preferably comprises an activation type phosphor comprising a base material and an activator. As the base material, a metal oxide, a metal sulfide, a metal sulfate or a halophosphoric acid compound, etc., may be used and as the activator, manganese, europium, cerium, praseodymium, lanthanum, gadolinium, terbium, dysprosium, holmium, erbium, thulium, yttrium, iron, zinc, etc., may be used.

[0038] As (b) the inorganic phosphor, there may be mentioned a red phosphor such as

[0039] CaAl.sub.12O.sub.19:Mn.sup.4+, CaAl.sub.12O.sub.19:Cr.sup.3+, Ca.sub.3Al.sub.2O.sub.6:Eu.sup.3+, Ca.sub.3(PO.sub.4).sub.2:Mn, NaCl:Mn, Mg.sub.2TiO.sub.4:Mn, MnCl.sub.2, etc., and a blue phosphor such as CaAl.sub.2O.sub.4:Eu.sup.2+, Ca.sub.12Al.sub.14O.sub.33:Ce.sup.3+, etc., and in the viewpoint of strengthening the ultraviolet-ray absorption effect of the external composition for skin of the present invention, aluminate phosphor is preferred, and an alkaline earth metal aluminate phosphor is more preferred.

[0040] As (b) the inorganic phosphor, calcium aluminate in which manganese or europium is activated is further preferred, and calcium manganese aluminate in which manganese is activated represented by the following formula (1);

Ca.sub.XAl.sub.yO.sub.(2X+3Y+4Z)/2:Mn.sup.4+.sub.Z   (1)

is particularly preferred.

[0041] In the formula, 0.1<X<1.05, 11.9<Y≦12 and 0.0005<Z<0.1.

[0042] The compound represented by the above-mentioned formula (1) is a compound in which Mn.sup.4+ is doped to the compound represented by the formula Ca.sub.xAl.sub.yO.sub.(2X+3Y+4Z)/2. CaAl.sub.12O.sub.19:Mn.sup.4+ is a red phosphor developed in 1971 (for example, see A. Bergstein et al, “Manganese-Activated Luminescence in Sr Al12 O19 and Ca Al12 O19” J. Electrochem. Soc., 118, p.116 (1971)). It has been reported that it shows red light-emission at around 657 nm by replacing an octahedral site of CaAl.sub.12O.sub.19 with Mn.sup.4+. Although this red phosphor has been researched and developed as a red phosphor for a white LED in recent years, no investigation has been made for formulating it into an external composition for skin.

[0043] The present inventors have found that the above-mentioned red phosphor is a safe material that does not adversely affect human health when it is used as a material of the external composition for skin, further safety of which is high, and exhibits an effect of markedly enhance the ultraviolet-ray absorption effect of (a) the ultraviolet-ray absorber. In addition, since it shows red light emission upon receiving the ultraviolet-ray, by using the external composition for skin of the present invention, not only sunscreen effect can be obtained but also coloration of the skin is improved, and further, the emitted red light can increase gene expression of the vasodilator, and it can be expected to have an effect to improve skin blood flow and improve facial color.

[0044] X, Y and Z in the above-mentioned formula (1) satisfy that, in the viewpoint that the effect of the above-mentioned present invention is excellent, X is more preferably a number exceeding 0.9 and less than 1.0. Z is more preferably a number exceeding 0.001 and less than 0.05.

[0045] The particle size of (b) the inorganic phosphor is preferably 1 μm to 100 μm, more preferably 1 to 50 μm, and particularly preferably 1 to 20 μm. By setting the particle size within the above range, the feeling of use of the external composition for skin of the present invention can be made excellent. The particle size is an average value of the values measured optional 250 particles in an image from the 1,000-fold image using a scanning type electron microscope (JSM840F manufactured by JOEL Ltd.). The particle size is a value measured with reference to the major axis of the particle.

[0046] (b) The inorganic phosphor is preferably an inorganic phosphor having a main wavelength in the region of 600 to 750 nm since it can be expected the effects that the red light emitted can increase gene expression of the vasodilator, improve the blood flow of the skin and make the face color good in addition to making the color of the skin good.

[0047] A process for producing (b) the inorganic phosphor is not particularly limited, and can be obtained by, for example, mixing a compound such as an alkaline earth metal, etc., an aluminum-source compound, a compound corresponding to the doped ion (for example, a manganese-source compound), which are starting materials, with a ratio corresponding to the molar ratio of the objective compound to form a precursor, and then, subjecting to firing.

[0048] As a method for mixing these starting compounds, the conventionally known method can be used. For example, there may be mentioned a method in which the starting compounds are made an aqueous dispersion, mixed by stirring or pulverizing using a wet media mill, and then, the whole mixture is dried by evaporation, and a method in which the starting compounds are mixed in a dry system using a general mixing device such as a Henschel mixer, a tumbler, etc., a hammer mill or a high-pressure air jet mill, or a combination thereof, etc.

[0049] As a method for firing, the conventionally known method can be used, and it may be, for example, a method in which firing is carried out by using a crucible made of ceramics, or a method in which firing is carried out while rotating by using a rotary kiln.

[0050] (b) The inorganic phosphor can be formulated as it is, in the external composition for skin and if necessary, it may be formulated after subjecting to various surface treatment by the conventionally known method.

[0051] Also, these surface treatments may be carried out one kind alone, or may be carried out the several kinds with laminated or mixed treatment.

[0052] The external composition for skin of the present invention preferably contains (b) the inorganic phosphor in a ratio of 0.1 to 15% by mass, more preferably 0.1 to 10% by mass. In addition, a formulation ratio (mass ratio) of (a) the ultraviolet-ray absorber and (b) the inorganic phosphor is preferably 100:1 to 1:100, more preferably 10:1 to 1:10. By containing (b) the inorganic phosphor with the above-mentioned ratio in the external composition for skin of the present invention, ultraviolet-ray absorbability can be more improved.

<Other Components>

[0053] The external composition for skin of the present invention may contain, in addition to the above-mentioned essential components, depending on the various purposes, other components such as inorganic particles other than (b) the inorganic phosphor, oils, a lipophilic nonioinic surfactant, a hydrophilic nonioinic surfactant, other surfactants, a sequestering agent, a natural water-soluble polymer, a semisynthetic water-soluble polymer, a synthetic water-soluble polymer, an inorganic water-soluble polymer, various kinds of extracts, various kinds of powders, a moisturizing ingredient, a polyhydric alcohol, a scrubbing agent, an ultraviolet-ray scattering component, a convergent component, a peptide or a derivative thereof, an amino acid or a derivative thereof, a cleaning component, a horny softening component, a cell activating component, an antiaging component, a blood circulation promoting component, a whitening component, a component having a preventive and/or repairing effect on DNA damage, an antiinflammatory component, an antioxidative component, Vitamins, a sebum adsorbing component, an antimicrobial component, etc., within the range which does not impair the effect of the present invention. In the external composition for skin of the present invention, these components may be formulated a single kind alone, or two or more kinds in combination. These respective components are not particularly limited as long as they can be used in the fields of pharmaceuticals, quasi-drugs, cosmetics, etc., and arbitrary ones can be optionally selected and used.

<Producing Method of External Composition for Skin >

[0054] A method for producing the external composition for skin of the present invention is not particularly limited, and may be produced by formulating (a) the ultraviolet-ray absorber and (b) the inorganic phosphor which are essential components, and a component(s) optionally selected from the other components, etc., and mixing by the conventional manner.

[0055] Use of the external composition for skin of the present invention is not particularly limited and may be used for, for example, a basic cosmetic such as lotion, moisturizing liquid, milky lotion, beauty liquid, pack, hand cream, body lotion and body cream; a cleansing cosmetic such as facial cleanser, makeup remover and body shampoo; a make-up cosmetic such as a foundation and make-up ground (in the basic cosmetic, the cleaning cosmetic and the make-up cosmetic, the sunscreen function (UV cutting function) may be specified explicitly or may not be specified); and a sunscreen cosmetic, etc. In addition, there may be mentioned a multifunctional type preparation in which the functions of these preparations are combined into one preparation. These preparations can be produced according to the conventional manner.

EXAMPLES

[0056] In the following, the present invention is explained in more detail by referring to Examples, but the present invention is not limited by these Examples. Incidentally, the unit of the numerical values in the respective Tables is % by mass otherwise specifically mentioned.

[Preparation of External Composition for Skin]

(1) Production of Inorganic Particles Containing Aluminate Phosphor (Calcium Manganese Aluminate) and Titanate Phosphor (Magnesium Manganese Titanate)

[0057] In water were charged 4.97 g of calcium carbonate (CWS-20 available from Sakai Chemical Industry, Co., Ltd.), manganese carbonate (0.06 g available from Chuo Denki), 32.0 g of aluminum oxide (RA-50 available from Sumitomo Chemical Industry Co., Ltd.) and 0.18 g of calcium fluoride (first class grade reagent, available from Wako Pure Chemical Industries, Ltd.) as a flux component, and 70.15 g of magnesium fluoride (special grade reagent, available from Wako Pure Chemical Industries, Ltd.), and the mixture was sufficiently mixed by using a planetary ball mill at 250 rpm for 30 minutes. The mixed slurry was dried by evaporation at 130° C. and the resulting solid material was crushed in a mortar to obtain firing precursor powder. Then, 15 g of the firing precursor was filled in a crucible made of alumina, and a temperature thereof was raised up to 1,600° C. with 200° C./hour in an ambient atmosphere, maintained at that state for 3 hours and then lowered to room temperature with 200° C./hour. The obtained fired product was crushed in a mortar to produce inorganic particles containing aluminate phosphor. Also, the titanate phosphor (magnesium manganese titanate) was produced in accordance with the production method of the above-mentioned aluminate phosphor.

(2) Preparation of External Composition for Skin

[0058] According to the prescriptions described in the following Tables 1 to 5, the external compositions for skin of Examples 1 to 6 and Comparative examples 1 to 7 were prepared according to the conventional manner. The following test was carried out with regard to the respective external compositions for skin, and evaluated.

TABLE-US-00001 TABLE 1 Formulation amount (%) Comparative Comparative Name of component example 1 example 2 Example 1 Purified water 93 95 90 (Hydroxyethyl acrylate/acryloyl 2 2 2 dimethyl taurine Na) copolymer (*1) 2-Ethylhexyl 5 0 5 paramethoxycinnamate (*2) Calcium manganese aluminate 0 3 3 Total 100 100 100 (*1) Simulgel NS (SEPPIC Co.) (*2) Ubinul MC80 (BASF)

TABLE-US-00002 TABLE 2 Formulation amount (%) Comparative Name of component example 3 Example 2 Purified water 86 83 (Hydroxyethyl acrylate/acryloyl 2 2 dimethyl taurine Na) copolymer (*1) Glyceryl tri(2-ethylhexanoate) 10 10 Hexyl 2-[4-(diethylamino)-2-hydroxy- 2 2 benzoyl]benzoate (*2) Calcium manganese aluminate 0 3 Total 100 100 (*1) Simulgel NS (SEPPIC Co.) (*2) Ubinul A Plus Granular (BASF)

TABLE-US-00003 TABLE 3 Formulation amount (%) Comparative Name of component example 4 Example 3 Purified water 93 93 (Hydroxyethyl acrylate/acryloyl dimethyl 2 2 taurine Na) copolymer (*1) Mixed solution of Hexyl 2-[4-(diethyl- 5 5 amino)-2-hydroxybenzoyl]benzoate and 2- ethylhexyl paramethoxycinnamate (35:65 in mass ratio) (*2) Calcium manganese aluminate 0 3 Total 100 100 (*1) Simulgel NS (SEPPIC Co.) (*2) Ubinul A Plus B (BASF)

TABLE-US-00004 TABLE 4 Formulation amount (%) Comparative Name of component example 5 Example 4 Purified water 93 90 (Hydroxyethyl acrylate/acryloyl 2 2 dimethyl taurine Na) copolymer (*1) 2-Ethylhexyl paramethoxycinnamate 5 5 (*2) Magnesium manganese titanate 0 3 Total 100 100 (*1) Simulgel NS (SEPPIC Co.) (*2) Ubinul MC80 (BASF)

TABLE-US-00005 TABLE 5 Formulation amount (%) Compar- Compar- ative Exam- ative Exam- exam- ple exam- ple Name of component ple 6 5 ple 7 6 Purified water 86 83 86 83 Glyceryl tri-2-ethylhexanoate 10 10 10 10 (*1) 6-(4-Methoxypheny)-1,3,5- 2 2 0 0 triazine (*2) 4-tert-Butyl-4′-memoxy- 0 0 2 2 dibenzoylmethane (*3) (Hydroxyethyl 2 2 2 2 acrylate/acryloyl dimethyl taurine Na) copolymer (*4) Calcium manganese aluminate 0 3 0 3 Total 100 100 100 100 (*1) MYRITOL GTEH (Cognis Japan Co.) (*2) TINOSORB S (Ciba-Geigy AG) (*3) Parsol 1789 (DSM Nutrition Japan K.K.) (*4) Simulgel NS (SEPPIC Co.)

<Ultraviolet Rays Absorbability Test>

[0059] The respective external compositions for skin were uniformly coated on a

[0060] PMMA plate so that these became 1.3 mg/cm.sup.2, and after drying for 15 minutes, UV spectrum thereof was measured by an ultraviolet visible light spectrophotometer V-650 (manufactured by JASCO Corporation). The results corresponding to Table 1 is shown in FIG. 1, the results corresponding to Table 2 is shown in FIG. 2, the results corresponding to Table 3 is shown in FIG. 3, the results corresponding to Table 4 is shown in FIG. 4, and the results corresponding to Table 5 is shown in FIG. 5.

[0061] It could be understood that ultraviolet-ray absorbability of the external composition for skin of Example 1 containing 2-ethylhexyl paramethoxy-cinnamate which is the ultraviolet-ray absorber (UV-B) and aluminate phosphor (calcium manganese aluminate) was markedly enhanced as compared with that of the external composition for skin of Comparative example 1 containing 2-ethylhexyl paramethoxycinnamate alone. Incidentally, ultraviolet-ray absorbability could scarcely be admitted only by the aluminate phosphor (Comparative example 2). Also, in the external composition for skin of Example 2 containing hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate which is the ultraviolet-ray absorber (UV-A), when aluminate phosphor (calcium manganese aluminate) was formulated thereto, enhancement of ultraviolet-ray absorbability could be admitted as compared to that of the external composition for skin of Comparative example 3 containing hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate alone. On the other hand, the external composition for skin of Example 3 containing a mixed solution of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate and 2-ethylhexyl paramethoxycinnamate which are the ultraviolet-ray absorbers (UV-A and B) and aluminate phosphor (calcium manganese aluminate) was found to be markedly enhanced in ultraviolet-ray absorbability as compared with that of the external composition for skin of Comparative example 4 containing hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]-benzoate and 2-ethylhexyl paramethoxycinnamate. Further, in the external composition for skin of Example 4 in which the aluminate phosphor to be used in combination with 2-ethylhexyl paramethoxycinnamate which is the ultraviolet-ray absorber (UV-B) was substituted with magnesium manganese titanate, it could be understood that the ultraviolet-ray absorbability thereof was markedly enhanced as compared with that of the external composition for skin of Comparative example 5 containing no magnesium manganese titanate (FIG. 4). Moreover, the external composition for skin of Example 5 containing 6-(4-methoxyphenyl)-1,3,5-triazine and aluminate phosphor (calcium manganese aluminate) which is the ultraviolet-ray absorber (UV-AB) was found to be markedly enhanced in ultraviolet-ray absorbability as compared with that of the external composition for skin of Comparative example 6 containing 6-(4-methoxyphenyl)-1,3,5-triazine alone. Furthermore, the external composition for skin of Example 6 containing 4-tert-butyl-4-methoxybenzoyl-methane which is the ultraviolet-ray absorber (UV-A) and aluminate phosphor (calcium manganese aluminate) was found to be markedly enhanced in ultraviolet-ray absorbability as compared with that of the external composition for skin of Comparative example 7 containing 4-tert-butyl-4-methoxybenzoylmethane alone.

<Measurement of gene expression amount of vasodilator>

[0062] Calcium manganese aluminate emits red light (wavelength: 660 nm) upon receiving ultraviolet-ray (excitation wavelength: 365 nm). Normal human vascular endothelial cells were irradiated with red light at an irradiation intensity of 0 to 1.32 J/cm.sup.2. Gene expression of vascular endothelial type Nitric Oxide Synthase (NOS3) which is a vasodilator was confirmed by the qRT-PCR method at the time of 24 hours after the irradiation. It was compared by making the expression amount under the non-irradiated conditions 1. For the respective conditions, the experimentswere carried out with n=3. The results are shown in FIG. 6.

[0063] As shown in FIG. 6, it could be confirmed that the gene expression amount of the vasodilator in vascular endothelial cells was increased depending on irradiation intensity by irradiating the red light.